Real-Life Evidence on Stroke Prevention in SPAF "RELIEF"


Phase N/A Results N/A

Summary of Purpose

To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 November 2015.

1 May 2015 28 May 2015 1 Sep 2015 1 Sep 2015 1 Nov 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Retrospective
  • Sampling: Non-Probability Sample